IMAPS-ETI-AG
13.1.2020 13:43:06 CET | Business Wire | Press release
The first ETI (Exchange Traded Instrument) under the public offering issuance program of Liechtenstein's iMaps ETI plc starts trading on the MTF of the Vienna Stock Exchange today.
The Haack Performance ETI was launched for the asset manager PP Asset Management, which is licensed by the German BAFIN. The note tracks the performance of the Haack investment strategy, which achieved a performance of almost 20% in the past year. "I am pleased that we start trading with our Actively Managed Certificate (AMC) on the Vienna Stock Exchange. This means that investors who do not want to follow the investment recommendations themselves all the time now also have easy access via stock exchange trading via their own broker to invest in our benchmark-independent product," says Hans-Jürgen Haack, Senior Manager at PP Asset Management and mastermind of the Haack investment strategy.
"We are pleased that we can welcome our first customer to the stock exchange for a public offering solution. The demand for these innovative investment vehicles or ETIs - Exchange Traded Instruments under our public offering program is increasing steadily and we will shortly announce further listings," summarizes Andreas Woelfl, founder & chairman of iMaps Capital Markets Group, the arranger.
"Exchange Listed Instruments" ETIs for short, issued by the Liechtenstein iMaps ETI AG combine the best of many worlds, public offering like an UCITS fund, exchange-traded similar to an ETF, flexible like an alternative investment fund and based on collateralization to Intertrust as a trustee in favor of ETI investors, to avoid the credit risk of the issuer. The demand shows us that we have met the needs of many asset managers with this financial innovation," summarizes Günter Woinar, CEO of iMaps Capital Markets European operations.
About iMaps ETI plc
iMaps ETI AG is an issuer of derivative securities in the Principality of Liechtenstein with a main business focus on Actively Managed Certificates and Fund-Linked Notes to be issued as a public offer in the EU & UK as well as private placements in Switzerland, Singapore and Hong Kong . The issuer is the wholly owned subsidiary of iMaps Capital Markets. The iMaps Capital Markets Group focuses on providing asset managers with the platform for issuing investment vehicles - either as actively managed certificates or fund linked notes with listing and offering in Europe and other jurisdictions. ETIs represent an interesting, rapidly growing and cost-efficient alternative to funds and thanks to the approved prospectus from iMaps ETI plc, there is the possibility of offering them to the public throughout the EU & UK.
Disclaimer: The prospectus for the issuance programme of Exchange Traded Instruments in the form of derivative securities got approved by FMA Liechtenstein and can be downloaded free of charge from the website www.imaps-capital.com/etis
Language: |
English |
Company: |
iMAPS ETI AG
|
Phone: |
+1345 232 1382 |
ISIN: |
CH0505798592 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200113005478/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release
New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
Boomi Teams up With Gong to Bring Revenue AI to Boomi Agentstudio14.5.2026 18:00:00 CEST | Press release
Gong's revenue AI is now natively available in the Boomi Enterprise Platform Boomi, the data activation company for AI, today announced a collaboration withGong, the leader in Revenue AI, to bring revenue signals captured in Gong natively into the Boomi Enterprise Platform. This collaboration enables enterprises to establish an active data foundation designed to transform customer conversations into coordinated, automated actions across systems and functions enterprise-wide with Boomi Agentstudio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514443012/en/ Boomi Teams Up with Gong to Bring Revenue AI to Boomi Agentstudio Gong goes beyond capturing deal activity to surface real-time insights into risk, buyer intent, competitive dynamics, and key engagement signals. That intelligence moves from conversation to coordinated action, flowing across CRM, ERP, product, and operational systems with the governance and security tha
Xsolla and Skich Announce Strategic Partnership to Bring Merchant of Record Payments to an Alternative Mobile Game Marketplace14.5.2026 18:00:00 CEST | Press release
Partnership Enables Developers To Monetize Games On The Skich Store With Xsolla Handling Payments, Tax Compliance, And Commerce Infrastructure Xsolla, a leading global video game commerce company, today announced a strategic partnership with Skich, an alternative mobile game marketplace operating on iOS in the EU under Apple's Digital Markets Act provisions and on Android globally. Under the agreement, Xsolla will serve as Merchant of Record for in-app purchases and paid game sales distributed through the Skich Store. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514867730/en/ Graphic: Xsolla Skich serves as an alternative to traditional mobile storefronts, offering developers a way to reach players outside platform-controlled distribution channels. The partnership with Xsolla enables Skich to offer a fully compliant payment and commerce layer, with Xsolla managing payment processing, tax collection, refunds, and regulat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom